# Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa

> **NCT02431143** · PHASE2 · COMPLETED · sponsor: **Drugs for Neglected Diseases** · enrollment: 30 (actual)

## Conditions studied

- Visceral Leishmaniasis

## Interventions

- **DRUG:** Miltefosine

## Key facts

- **NCT ID:** NCT02431143
- **Lead sponsor:** Drugs for Neglected Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2016-04
- **Final completion:** 2016-09
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2016-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02431143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02431143, "Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02431143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*